Aspira Women’s Health Inc. last reported quarterly results on Nov 14, 2025, for Q3 FY2025 (the quarter ended Sep 30, 2025): revenue of $2.3 million (+2.1% year over year) and diluted EPS of -$0.13. It usually reports 44–49 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 44–49 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 14, 2025
45 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
2
+2.1%
|
-5
-37.9%
|
-0.13
+43.5%
|
|
Aug 13, 2025
44 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
2
-0.8%
|
-3
+24.5%
|
-0.07
+75.0%
|
|
May 19, 2025
49 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
2
+5.9%
|
-2
+60.0%
|
-0.09
+76.9%
|
|
Nov 14, 2024
45 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
2
+1.8%
|
-4
+24.6%
|
-0.23
+52.1%
|
|
Aug 12, 2024
43 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
|
May 15, 2024
45 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
|
Jan 25, 2024
25 days after quarter end
|
—
ended Dec 31, 2023
|
—
|
—
|
—
|
|
Nov 13, 2023
44 days after quarter end
|
—
ended Sep 30, 2023
|
—
|
—
|
—
|
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- AWHL (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 926617
- Former names
- VERMILLION, INC. (until Jun 10, 2020); CIPHERGEN BIOSYSTEMS INC (until Aug 17, 2007)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.